Skip to main content
Erschienen in: Herz 6/2013

01.09.2013 | Review article

Natriuretic peptide-guided therapy

Further research required for still-unresolved issues

verfasst von: Dr. R. De Vecchis, C. Esposito, S. Cantatrione

Erschienen in: Herz | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

It has been asserted that serial measurements of natriuretic peptides (NPs), i.e., B-type natriuretic peptide (BNP) or the amino-terminal fragment of pro-B-type natriuretic peptide (NT-pro BNP), could help modulate more accurately the intensity of drug treatment in patients with chronic heart failure (CHF). Nevertheless, there are still several open questions about the presumed role of NP-guided pharmacologic adjustment as a valuable strategy in this setting. In this review, we outline the main randomized controlled trials (RCTs) carried out to date regarding NP-guided therapy in CHF patients and we focus on some of the still-unresolved issues. In particular, we discuss which NP plasma level should be assumed as the optimal target level to be attained, and we debate the possible influence exerted by different age classes on clinical end points during NP-guided therapy. The possible advantages and limitations for the cardiovascular system arising from the functional activation of NPs in CHF patients are also discussed. Although the pooling of data derived from the RCTs demonstrates an overall effect of slightly significant improvement in clinical outcomes with the NP-guided approach, we have noted that there are some relatively large studies that failed to document a significant clinical improvement in terms of mortality and morbidity using an NP-guided strategy. Thus, in our opinion, larger and better conducted trials addressing the unresolved issues of NP-guided therapy should be undertaken in the future.
Literatur
1.
Zurück zum Zitat Troughton RW, Frampton CM, Yandle TG et al (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (NT-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRef Troughton RW, Frampton CM, Yandle TG et al (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (NT-BNP) concentrations. Lancet 355:1126–1130PubMedCrossRef
2.
Zurück zum Zitat Jourdain P, Jondeau G, Funck F et al (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739PubMedCrossRef Jourdain P, Jondeau G, Funck F et al (2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49:1733–1739PubMedCrossRef
3.
Zurück zum Zitat Lainchbury JG, Troughton RW, Strangman KM et al (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55(1):53–60PubMedCrossRef Lainchbury JG, Troughton RW, Strangman KM et al (2009) N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 55(1):53–60PubMedCrossRef
4.
Zurück zum Zitat Pfisterer M, Buser P, Rickli H et al (2009) TIME-CHF investigators. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA 301(4):383–392PubMedCrossRef Pfisterer M, Buser P, Rickli H et al (2009) TIME-CHF investigators. BNP-guided vs symptom-guided heart failure therapy: the trial of intensified vs standard medical therapy in elderly patients with congestive heart failure (TIME-CHF) randomized trial. JAMA 301(4):383–392PubMedCrossRef
5.
Zurück zum Zitat Berger R, Moertl D, Peter S et al (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55(7):645–653PubMedCrossRef Berger R, Moertl D, Peter S et al (2010) N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. J Am Coll Cardiol 55(7):645–653PubMedCrossRef
6.
Zurück zum Zitat Eurlings LW, Pol PE van, Kok WE et al (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can pro-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart failure morbidity and mortality?) study. J Am Coll Cardiol 56(25):2090–2100PubMedCrossRef Eurlings LW, Pol PE van, Kok WE et al (2010) Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can pro-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart failure morbidity and mortality?) study. J Am Coll Cardiol 56(25):2090–2100PubMedCrossRef
7.
Zurück zum Zitat Persson H, Erntell H, Eriksson B et al (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure—SIGNAL-HF (Swedish Intervention study—guidelines and NT-proBNP analysis in heart failure). Eur J Heart Fail 12:1300–1308PubMedCrossRef Persson H, Erntell H, Eriksson B et al (2010) Improved pharmacological therapy of chronic heart failure in primary care: a randomized study of NT-proBNP guided management of heart failure—SIGNAL-HF (Swedish Intervention study—guidelines and NT-proBNP analysis in heart failure). Eur J Heart Fail 12:1300–1308PubMedCrossRef
8.
Zurück zum Zitat Shah MR, Califf RM, Nohria A et al (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17:613–621PubMedCrossRef Shah MR, Califf RM, Nohria A et al (2011) The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. J Card Fail 17:613–621PubMedCrossRef
9.
Zurück zum Zitat Gaggin HK, Mohammed AA, Bhardwaj A et al (2012) Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 18:626–634PubMedCrossRef Gaggin HK, Mohammed AA, Bhardwaj A et al (2012) Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. J Card Fail 18:626–634PubMedCrossRef
10.
Zurück zum Zitat Maeda K, Tsutamoto T, Wada A et al (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825–832PubMedCrossRef Maeda K, Tsutamoto T, Wada A et al (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825–832PubMedCrossRef
11.
Zurück zum Zitat Nakagawa O, Ogawa Y, Itoh H et al (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 96:1280–1287PubMedCrossRef Nakagawa O, Ogawa Y, Itoh H et al (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an “emergency” cardiac hormone against ventricular overload. J Clin Invest 96:1280–1287PubMedCrossRef
12.
Zurück zum Zitat Mair J (2001) The utility of brain natriuretic peptides in patients with heart failure and coronary artery disease. In: Adams JE III, Jaffe AS, Apple FS, Wu AHB (Hrsg) Markers in cardiology: current and future applications, Chapter 20. Futura Publishing Company, Armonk, S 235–247 Mair J (2001) The utility of brain natriuretic peptides in patients with heart failure and coronary artery disease. In: Adams JE III, Jaffe AS, Apple FS, Wu AHB (Hrsg) Markers in cardiology: current and future applications, Chapter 20. Futura Publishing Company, Armonk, S 235–247
13.
Zurück zum Zitat Maisel A, Mueller C, Adams K Jr et al (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10:824–839PubMedCrossRef Maisel A, Mueller C, Adams K Jr et al (2008) State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 10:824–839PubMedCrossRef
14.
Zurück zum Zitat Yoshimura M, Mizuno Y, Nakayama M et al (2002) B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112(9):716–720PubMedCrossRef Yoshimura M, Mizuno Y, Nakayama M et al (2002) B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112(9):716–720PubMedCrossRef
15.
Zurück zum Zitat Latini R, Masson S, Anand I et al (2002) Valsartan heart failure trial investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (Val-HeFT). Circulation 106(19):2454–2458PubMedCrossRef Latini R, Masson S, Anand I et al (2002) Valsartan heart failure trial investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the valsartan heart failure trial (Val-HeFT). Circulation 106(19):2454–2458PubMedCrossRef
16.
Zurück zum Zitat Troughton RW, Frampton CM, Nicholls MG (2010) Biomarker-guided treatment of heart failure: still waiting for a definitive answer. J Am Coll Cardiol 56(25):2101–2104PubMedCrossRef Troughton RW, Frampton CM, Nicholls MG (2010) Biomarker-guided treatment of heart failure: still waiting for a definitive answer. J Am Coll Cardiol 56(25):2101–2104PubMedCrossRef
17.
Zurück zum Zitat Wu AH, Smith A (2004) Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 15(6):355–358CrossRef Wu AH, Smith A (2004) Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure. Eur J Heart Fail 15(6):355–358CrossRef
18.
Zurück zum Zitat O’Hanlon R, O’Shea P, Ledwidge M et al (2007) The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13:50–55CrossRef O’Hanlon R, O’Shea P, Ledwidge M et al (2007) The biologic variability of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide in stable heart failure patients. J Card Fail 13:50–55CrossRef
19.
Zurück zum Zitat Bruins S, Fokkema MR, Römer JW et al (2004) Muskiet FA High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50(11):2052–2058PubMedCrossRef Bruins S, Fokkema MR, Römer JW et al (2004) Muskiet FA High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 50(11):2052–2058PubMedCrossRef
20.
Zurück zum Zitat Wu AH (2006) Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152(5):828–834PubMedCrossRef Wu AH (2006) Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152(5):828–834PubMedCrossRef
21.
Zurück zum Zitat Miller WL, Hartman KA, Grill DE et al (2009) Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 55(1):78–84PubMedCrossRef Miller WL, Hartman KA, Grill DE et al (2009) Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. Clin Chem 55(1):78–84PubMedCrossRef
22.
Zurück zum Zitat Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158:422–430PubMedCrossRef Felker GM, Hasselblad V, Hernandez AF, O’Connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158:422–430PubMedCrossRef
23.
Zurück zum Zitat Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 170:507–514PubMedCrossRef Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 170:507–514PubMedCrossRef
24.
Zurück zum Zitat Forman DE, Rich MW, Alexander KP et al (2011) Cardiac care for older adults: time for a new paradigm. J Am Coll Cardiol 57:1801–1810PubMedCrossRef Forman DE, Rich MW, Alexander KP et al (2011) Cardiac care for older adults: time for a new paradigm. J Am Coll Cardiol 57:1801–1810PubMedCrossRef
25.
Zurück zum Zitat Luchner A, Stevens TL, Borgeson DD et al (1998) Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274:H1684–H1689PubMed Luchner A, Stevens TL, Borgeson DD et al (1998) Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 274:H1684–H1689PubMed
26.
Zurück zum Zitat Shimizu H, Masuta K, Aono K et al (2002) Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316:129–135PubMedCrossRef Shimizu H, Masuta K, Aono K et al (2002) Molecular forms of human brain natriuretic peptide in plasma. Clin Chim Acta 316:129–135PubMedCrossRef
27.
Zurück zum Zitat Hawkridge AM, Heublein DM, Bergen HR III et al (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102:17442–17447PubMedCrossRef Hawkridge AM, Heublein DM, Bergen HR III et al (2005) Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc Natl Acad Sci USA 102:17442–17447PubMedCrossRef
28.
Zurück zum Zitat Liang F, O’Rear J, Schellenberger U et al (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071–1078PubMedCrossRef Liang F, O’Rear J, Schellenberger U et al (2007) Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 49:1071–1078PubMedCrossRef
29.
Zurück zum Zitat Lam CS, Burnett JC Jr, Costello-Boerrigter L et al (2007) Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 49:1193–202PubMedCrossRef Lam CS, Burnett JC Jr, Costello-Boerrigter L et al (2007) Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 49:1193–202PubMedCrossRef
30.
Zurück zum Zitat Chen HH, Schirger JA, Chau WL et al (1999) Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 100:2443–2448PubMedCrossRef Chen HH, Schirger JA, Chau WL et al (1999) Renal response to acute neutral endopeptidase inhibition in mild and severe experimental heart failure. Circulation 100:2443–2448PubMedCrossRef
31.
Zurück zum Zitat Charloux A, Piquard F, Doutreleau S et al (2003) Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33:769–778PubMedCrossRef Charloux A, Piquard F, Doutreleau S et al (2003) Mechanisms of renal hyporesponsiveness to ANP in heart failure. Eur J Clin Invest 33:769–778PubMedCrossRef
32.
Zurück zum Zitat Miller WL, Hartman KA, Burritt MF et al (2005) Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 51:569–577PubMedCrossRef Miller WL, Hartman KA, Burritt MF et al (2005) Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. Clin Chem 51:569–577PubMedCrossRef
33.
Zurück zum Zitat Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745–751PubMedCrossRef Raymond I, Groenning BA, Hildebrandt PR et al (2003) The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population. Heart 89:745–751PubMedCrossRef
34.
Zurück zum Zitat Rademaker MT, Charles CJ, Kosoglou T et al (1997) Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 273:H2372–H2379PubMed Rademaker MT, Charles CJ, Kosoglou T et al (1997) Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure. Am J Physiol 273:H2372–H2379PubMed
35.
Zurück zum Zitat Potter LR, Hunter T (2001) Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 276:6057–6060PubMedCrossRef Potter LR, Hunter T (2001) Guanylyl cyclase-linked natriuretic peptide receptors: structure and regulation. J Biol Chem 276:6057–6060PubMedCrossRef
36.
Zurück zum Zitat Packer M (2003) Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Focused perspective. Circulation 108:2950–2953PubMedCrossRef Packer M (2003) Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure? Focused perspective. Circulation 108:2950–2953PubMedCrossRef
37.
Zurück zum Zitat MacFadyen RJ, Ng Kam Chuen MJ, Davis RC (2010) Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy? Eur J Heart Fail 12:649–652PubMedCrossRef MacFadyen RJ, Ng Kam Chuen MJ, Davis RC (2010) Loop diuretic therapy in left ventricular systolic dysfunction: has familiarity bred contempt for a critical but potentially nephrotoxic cardio renal therapy? Eur J Heart Fail 12:649–652PubMedCrossRef
38.
Zurück zum Zitat Ronco C, Haapio M, House AA et al (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527–1539PubMedCrossRef Ronco C, Haapio M, House AA et al (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527–1539PubMedCrossRef
Metadaten
Titel
Natriuretic peptide-guided therapy
Further research required for still-unresolved issues
verfasst von
Dr. R. De Vecchis
C. Esposito
S. Cantatrione
Publikationsdatum
01.09.2013
Verlag
Urban & Vogel
Erschienen in
Herz / Ausgabe 6/2013
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI
https://doi.org/10.1007/s00059-013-3772-8

Weitere Artikel der Ausgabe 6/2013

Herz 6/2013 Zur Ausgabe

Aktuelle Kardiologie

Aktuelle Kardiologie

So beeinflussen Herzinfarkte auf lange Sicht die Sterblichkeit

20.06.2024 ST-Hebungsinfarkt Nachrichten

Wie hoch ist bei Patienten, die nach einem ST-Hebungs-Myokardinfarkt die initiale Hochrisikophase überleben, auf lange Sicht das Sterberisiko? Eine Studie aus Dänemark liefert dazu nun aufschlussreiche Daten.

Protonenpumpenhemmer stoppt Arrhythmie

20.06.2024 Protonenpumpenhemmstoffe Nachrichten

Wenn Nervenfasern aus dem Magen und dem Herzen im Gehirn dicht beieinander liegen, kann auch mal etwas schiefgehen: So lässt sich erklären, weshalb Schmerzen durch einen Magentumor bei einem Mann eine ventrikuläre Extrasystolie auslösen – und PPI diese beenden.

Ob Apixaban nützt oder schadet, entscheidet der CHA2DS2-VASc-Score

20.06.2024 Therapie des Vorhofflimmerns Nachrichten

Patienten mit subklinischem Vorhofflimmern tragen ein erhöhtes Risiko für Schlaganfälle. Da stellt sich die Frage nach einer medikamentösen Antikoagulation. Offenbar hängt es aber vom CHA2DS2-VASc-Score ab, ob die Gabe von Apixaban von Vorteil ist.

Wie SGLT2-Hemmer es schaffen, die Mortalität zu reduzieren

20.06.2024 Kardiologische Therapie Nachrichten

SGLT2-Hemmer verhindern keine Herzinfarkte oder Schlaganfälle. Aber sie reduzieren die kardiovaskuläre Mortalität bei einem breiten Spektrum von Patienten. Wie sie das schaffen, verdeutlicht eine Metaanalyse von Daten aus elf randomisierten Studien.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.